| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1052576760 |
| P356 | DOI | 10.1007/S00405-016-4273-1 |
| P698 | PubMed publication ID | 27538737 |
| P50 | author | Cemal Cingi | Q57168875 |
| Nuray Bayar Muluk | Q89554735 | ||
| P2093 | author name string | Murat Kar | |
| Emine Güven Sakalar | |||
| P2860 | cites work | Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma | Q24564777 |
| Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice | Q24600284 | ||
| Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes | Q24633568 | ||
| Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor | Q24647514 | ||
| Update on the Management of Aspirin-Exacerbated Respiratory Disease | Q26749097 | ||
| Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases | Q26778683 | ||
| Tailored therapy for severe asthma | Q27016035 | ||
| Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis | Q28167195 | ||
| Aspirin sensitivity and IgE antibodies to Staphylococcus aureus enterotoxins in nasal polyposis: studies on the relationship | Q28167356 | ||
| Aspirin-induced asthma: clinical aspects, pathogenesis and management | Q28171145 | ||
| Association of thromboxane A2 receptor gene polymorphism with the phenotype of acetyl salicylic acid-intolerant asthma | Q28175608 | ||
| Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis | Q28176722 | ||
| Chronic hyperplastic eosinophilic sinusitis as a predictor of aspirin-exacerbated respiratory disease | Q28182005 | ||
| Intranasal lysine-aspirin in aspirin-sensitive nasal polyposis: a controlled trial | Q28186662 | ||
| An open audit of montelukast, a leukotriene receptor antagonist, in nasal polyposis associated with asthma | Q28189893 | ||
| Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial | Q28192038 | ||
| Salicylic acid in soups prepared from organically and non-organically grown vegetables | Q28192469 | ||
| The natural history and clinical characteristics of aspirin-exacerbated respiratory disease | Q28194291 | ||
| Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease | Q28194657 | ||
| Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atherosclerotic vascular disease | Q28195300 | ||
| Natural history and clinical features of aspirin-exacerbated respiratory disease | Q28195561 | ||
| Bronchial mast cells are the dominating LTC4S-expressing cells in aspirin-tolerant asthma | Q28196491 | ||
| Clinical and pathologic perspectives on aspirin sensitivity and asthma | Q28200628 | ||
| Specific immunoglobulin E for staphylococcal enterotoxins in nasal polyps from patients with aspirin-intolerant asthma | Q28210335 | ||
| Sodium salicylate sensitivity in an asthmatic patient with aspirin sensitivity | Q28211022 | ||
| EAACI/GA2LEN guideline: aspirin provocation tests for diagnosis of aspirin hypersensitivity | Q28211293 | ||
| Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma | Q28211753 | ||
| Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease | Q28213966 | ||
| Eicosanoids, aspirin-intolerance and the upper airways--current standards and recent improvements of the desensitization therapy | Q28218140 | ||
| The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict? | Q28222303 | ||
| Cysteinyl leukotrienes and their receptors; emerging concepts | Q28243252 | ||
| Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes, and preservatives in a population of perennial asthmatics | Q28326900 | ||
| Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease | Q30410446 | ||
| Nasal lysine aspirin challenge in the diagnosis of aspirin - exacerbated respiratory disease: asthma and rhinitis | Q30426324 | ||
| Modulation by aspirin of nuclear phospho-signal transducer and activator of transcription 6 expression: Possible role in therapeutic benefit associated with aspirin desensitization | Q30449068 | ||
| Aspirin sensitivity and chronic rhinosinusitis with polyps: a fatal combination | Q30464467 | ||
| Aspirin-exacerbated respiratory disease: evaluation and management | Q30477625 | ||
| Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma | Q33905623 | ||
| Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma | Q33921113 | ||
| Intolerance to aspirin. Clinical studies and consideration of its pathogenesis | Q34236999 | ||
| Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatic subjects. | Q34295682 | ||
| Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature | Q34441715 | ||
| European Position Paper on Rhinosinusitis and Nasal Polyps 2012. | Q34640008 | ||
| Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease | Q36158395 | ||
| Effect of endobronchial aspirin challenge on inflammatory cells in bronchial biopsy samples from aspirin-sensitive asthmatic subjects | Q36505616 | ||
| Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma | Q36573399 | ||
| Sinonasal outcomes after endoscopic sinus surgery in asthmatic patients with nasal polyps: a difference between aspirin-tolerant and aspirin-induced asthma? | Q37162102 | ||
| Prostaglandin E2 deficiency causes a phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes | Q37240446 | ||
| Aspirin sensitivity and desensitization for asthma and sinusitis | Q37390928 | ||
| Cross-reactivity to Acetaminophen and Celecoxib According to the Type of Nonsteroidal Anti-inflammatory Drug Hypersensitivity. | Q37605444 | ||
| A systematic review of salicylates in foods: estimated daily intake of a Scottish population. | Q37847113 | ||
| Rhinosinusitis and nasal polyps in aspirin-exacerbated respiratory disease | Q38103708 | ||
| Aspirin and salicylate in respiratory disease | Q38128829 | ||
| Evidence-based approach to aspirin desensitization in aspirin-exacerbated respiratory disease | Q38173911 | ||
| Safety risks for patients with aspirin-exacerbated respiratory disease after acute exposure to selective nonsteroidal anti-inflammatory drugs and COX-2 inhibitors: Meta-analysis of controlled clinical trials | Q38175544 | ||
| Upper airways in aspirin-exacerbated respiratory disease. | Q38302625 | ||
| Outcomes of modified endoscopic Lothrop in aspirin-exacerbated respiratory disease with nasal polyposis. | Q38780339 | ||
| Control of arachidonate levels within inflammatory cells | Q40941849 | ||
| Fatty acid substrate specificities of human prostaglandin-endoperoxide H synthase-1 and -2. Formation of 12-hydroxy-(9Z, 13E/Z, 15Z)- octadecatrienoic acids from alpha-linolenic acid | Q41310266 | ||
| Pathogenic Mechanisms and In Vitro Diagnosis of AERD. | Q41898865 | ||
| Cutting edge: Leukotriene C4 activates mouse platelets in plasma exclusively through the type 2 cysteinyl leukotriene receptor | Q42153378 | ||
| The effect of aspirin desensitization on novel biomarkers in aspirin-exacerbated respiratory diseases. | Q42930593 | ||
| Superantigens and chronic rhinosinusitis: skewing of T-cell receptor V beta-distributions in polyp-derived CD4+ and CD8+ T cells | Q42942766 | ||
| Nonsteroidal anti-inflammatory drug hypersensitivity syndrome. A multicenter study. I. Clinical findings and in vitro diagnosis. | Q43253611 | ||
| Predicting outcomes of oral aspirin challenges in patients with asthma, nasal polyps, and chronic sinusitis | Q44432091 | ||
| Dupilumab in persistent asthma with elevated eosinophil levels | Q44480181 | ||
| Increased levels of cysteinyl-leukotrienes in saliva, induced sputum, urine and blood from patients with aspirin-intolerant asthma. | Q46403708 | ||
| Survey-Defined Patient Experiences With Aspirin-Exacerbated Respiratory Disease | Q48041264 | ||
| Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis | Q49046464 | ||
| Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma | Q49152600 | ||
| A suggested shorthand nomenclature for the eicosanoids | Q50708164 | ||
| Eosinophil activation and novel mediators in the aspirin-induced nasal response in AERD. | Q50891793 | ||
| Treatment of aspirin exacerbated respiratory disease with a low salicylate diet: a pilot crossover study. | Q51688540 | ||
| The Pivotal Role of 5-Lipoxygenase Products in the Reaction of Aspirin-sensitive Asthmatics to Aspirin | Q57240791 | ||
| The diagnosis of aspirin idiosyncrasy by analgesic challenge | Q67797210 | ||
| The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma | Q68026345 | ||
| Sensitivity to non-acetylated salicylates in a patient with asthma, nasal polyps, and rheumatoid arthritis | Q69584241 | ||
| Aspirin intolerance in asthma *1, *2Detection by oral challenge | Q70482344 | ||
| Recent studies on the chemical synthesis of eicosanoids | Q71228909 | ||
| Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma | Q72352958 | ||
| Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics | Q74490010 | ||
| Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive asthma | Q74587028 | ||
| EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists | Q83792713 | ||
| Dupilumab treatment in adults with moderate-to-severe atopic dermatitis | Q87371931 | ||
| P433 | issue | 3 | |
| P921 | main subject | aspirin | Q18216 |
| respiratory disease | Q3286546 | ||
| P304 | page(s) | 1291-1300 | |
| P577 | publication date | 2016-08-18 | |
| P1433 | published in | European Archives of Oto-Rhino-Laryngology | Q2624005 |
| P1476 | title | Aspirin-exacerbated respiratory disease and current treatment modalities | |
| P478 | volume | 274 |
Search more.